Pemetrexed + Erlotinib
ApprovedTerminated 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Feb 28, 2018 → Nov 14, 2018
NCT ID
NCT03460678About Pemetrexed + Erlotinib
Pemetrexed + Erlotinib is a approved stage product being developed by Hikma Pharmaceuticals for Carcinoma, Non-Small-Cell Lung. The current trial status is terminated. This product is registered under clinical trial identifier NCT03460678. Target conditions include Carcinoma, Non-Small-Cell Lung.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03460678 | Approved | Terminated |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung